MarginsXMarginsX
Home › Markets › Health Care › PTN

Palatin Technologies Inc. (PTN)

PTN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.13
-1.69% on the day
Market cap
$10.9M
Nano cap
Revenue · 2026
$8.8M
Prior year not contiguous
Net income · 2026
-$8.4M
-94.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/0001493152-26-044572-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerPTN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000911216
SEC industry codePharmaceutical Preparations
Incorporated inNJ

Financials · 2026

LineValue
Revenue$8.8M
Net income-$8.4M
Operating income-$8.7M
Net margin-94.9%
Operating margin-98.2%
Revenue growthNo prior-year revenue to compare
Cash$7.5M
Total assets$8.5M
P/E (computed)Net income was not positive
P/S (computed)1.2×

Warning signs

Cash runway
6.6 months
$7.5M cash at June 30, 2026
Share count, 1 year
+83.0%
2025-09-19 to 2026-09-25 · +645.4% over 3 years
Going-concern doubt
Yes
10-K filed September 28, 2026
Insider net buying, 12 months
-$9K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Risks Related to Our Financial Results and Need for Financing Our management has determined that there is substantial doubt about our ability to continue as a going concern, which may make it more difficult and more expensive for us to raise capital."
10-K 2026-09-28
Cash and burn$7.5M cash; operating cash flow -$3.4M a quarter.Report 2026-06-30
Shares outstanding1,780,939 (2026-09-25); 973,291 a year earlier; 11,946,646 three years earlier. 3y figure adjusted for splits (1-for-50 overall).Cover page 2026-09-25
Reverse splits, 3 years1; latest 1-for-50 on 2025-08-12Source 2025-08-12
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25 filed25 2026-05-28
AuditorKPMG LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-10-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $9K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
$301K-$4.4M-$2.7M$7.5MNo debt tags$13.2M10-K 2026-09-28
Q3 2026
2026-03-31
$3.9M-$1.4M-$4.4M$10.2MNo debt tags$12.9M10-Q 2026-05-13
Q2 2026
2025-12-31
$116K-$7.3M-$4.8M$14.5MNo debt tags$8.9M10-Q 2026-02-17
Q1 2026
2025-09-30
$8.8M$4.7M-$1.6M$1.3MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-06-30
$0-$2.2M-$4.1M$2.6MNo debt tags$010-K 2025-09-23
Q3 2025
2025-03-31
$0-$4.8M-$5.4M$2.5MNo debt tagsNeeds four quarters10-Q 2025-05-14
Q2 2025
2024-12-31
Not filed-$2.4M-$4.8M$3.4MNo debt tagsNeeds four quarters10-Q 2026-02-17
Q1 2025
2024-09-30
$0-$7.8M-$7.0M$2.4MNo debt tags$2.4M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42025-11-12
Latest annual report10-K2026-09-28
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-08-03
Latest proxyDEF 14A2026-06-25

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.6%
1 month-23.9%
3 months-37.7%
Year to date-59.5%
1 year-42.3%
From 52-week high-77.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HINDVyome Holdings Inc.$1.53-3.16%$10.7M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
BIVIBioVie Inc.$1.08-4.42%$11.6M
BFRIBiofrontera Inc.$0.5700-18.58%$10.2M
CLRBCellectar Biosciences Inc.$1.01-11.40%$10.1M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier